Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 7/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | PTP4A1 | Q93096 | 1/20 | 0.53 |
| ▸ | MIF | P14174 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.51 |
| ▸ | USP2 | O75604 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4961560 | 1.00 | CYP2C9 (0.69) | CYP2C9ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL2755215 | 1.00 | CYP2C9 (0.69) | CYP2C9ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL6848669 | 0.88 | CYP2C9 (0.61) | CYP2C9ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL19355063 | 0.87 | CYP2C9 (0.65) | CYP2C9ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL8025998 | 0.87 | CYP2C9 (0.65) | CYP2C9ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL1680434 | 0.87 | CYP2C9 (0.65) | CYP2C9ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL1680433 | 0.87 | CYP2C9 (0.65) | CYP2C9ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL8027197 | 0.85 | CYP2C9 (0.62) | CYP2C9ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL9545461 | 0.85 | CYP2C9 (0.62) | CYP2C9ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL5323687 | 0.85 | CYP2C9 (0.62) | CYP2C9ALDH1A1TSHRMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20180214418-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN | VERSEON INTERNATIONAL CORPORATION | 2018-08-02 | — | — | US | disclosed |
| US-20180160686-A1 | DIARYLAZOLE COMPOUND AND HARMFUL ORGANISM CONTROL AGENT | NIPPON SODA CO., LTD. (JP) | 2018-06-14 | — | — | US | disclosed |
| US-9963440-B2 | Multisubstituted aromatic compounds as inhibitors of thrombin | VERSEON CORPORATION (US) | 2018-05-08 | — | — | US | disclosed |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-05-03 | — | — | US | disclosed |
| US-20180064698-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INTERNATIONAL CORPORATION | 2018-03-08 | — | — | US | disclosed |
| US-9840516-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170326125-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN | VERSEON INTERNATIONAL CORPORATION | 2017-11-16 | — | — | US | disclosed |
| US-20170258775-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INTERNATIONAL CORPORATION | 2017-09-14 | — | — | US | disclosed |
| US-9718815-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| WO-2003063909-A1 | RESPONSIVE MICROGEL AND METHODS RELATED THERETO | SUPRATEK PHARMA INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| US-6491903-B1 | NARROW MOLECULAR WEIGHT DISTRIBUTION SHELL-CORE POLYMERS HAVING HYDROPHILIC, CROSSLINKED PERMEABLE SHELLS AND HYDROPHOBIC CORES, USED FOR REDUCING BLOOD CHOLESTEROL AND BILE ACID UPTAKE IN INTERSTINES; DRUG DELIVERY | WASHINGTON UNIVERSITY | 2002-12-10 | — | — | US | disclosed |
| US-6383500-B1 | Particles comprising amphiphilic copolymers, having a crosslinked shell domain and an interior core domain, useful for pharmaceutical and other applications | WASHINGTON UNIVERSITY | 2002-05-07 | — | — | US | disclosed |
| EP-0910351-A1 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. Searle & Co. (US) | 1999-04-28 | — | — | EP | disclosed |
| EP-0907666-A1 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. Searle & Co. (US) | 1999-04-14 | — | — | EP | disclosed |
| US-5708180-A | CYCLIZATION OF UNSATURATED NITRILE, AMIDE OR OXIME | BAYER AKTIENGESELLSCHAFT (DE) | 1998-01-13 | — | — | US | disclosed |
| WO-1997049736-A2 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. SEARLE AND CO. (US) | 1997-12-31 | — | — | WO | disclosed |
| WO-1997049387-A1 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. SEARLE AND CO. (US) | 1997-12-31 | — | — | WO | disclosed |
| US-4261988-A | ANTICHOLESTEROL AGENTS USED IN ANIMAL HUSBANDRY | BAYER AKTIENGESELLSCHAFT (DE) | 1981-04-14 | — | — | US | disclosed |
| US-4235923-A | Esters of 3-substituted-2-(aminocarbonyl)oxiranecarboxylic acids as lipogenesis inhibitors | SHELL OIL COMPANY (US) | 1980-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180064698-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS | SPINT2, PRSS1, SERPINB1 | CYP2C9 1634/4885ALDH1A1 2728/4885TSHR 3654/4885 |
| US-20170326125-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN | TFPI, PLAT, SERPINC1 | CYP2C9 385/4885ALDH1A1 3080/4885TSHR 702/4885 |
| US-20180214418-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN | TFPI, PLAT, SERPINC1 | CYP2C9 385/4885ALDH1A1 3080/4885TSHR 702/4885 |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | CYP2C9 2134/4885ALDH1A1 4009/4885TSHR 2014/4885 |
| US-20180160686-A1 | DIARYLAZOLE COMPOUND AND HARMFUL ORGANISM CONTROL AGENT | L3MBTL1, L3MBTL3, L3MBTL4 | CYP2C9 543/4885ALDH1A1 230/4885TSHR 3058/4885 |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | CYP2C9 3388/4885ALDH1A1 4178/4885TSHR 1662/4885 |
| US-20170258775-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS | SPINT2, PRSS1, SERPINB1 | CYP2C9 1634/4885ALDH1A1 2728/4885TSHR 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.